DexCom, Inc. $DXCM Stake Lessened by Kovitz Investment Group Partners LLC

Key Points

• Kovitz Investment Group Partners LLC reduced its stake in DexCom, Inc. by 72.5%, selling 17,943 shares and ending up with 6,804 shares valued at approximately $465,000.
• Several analysts have recently issued positive ratings on DexCom, with price targets ranging from $100.00 to $106.00, indicating a consensus rating of "Moderate Buy".
• In August, Director Mark G. Foletta sold 2,750 shares at an average price of $81.06, decreasing his ownership by 5.10%.

Kovitz Investment Group Partners LLC trimmed its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 72.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 6,804 shares of the medical device company's stock after selling 17,943 shares during the period. Kovitz Investment Group Partners LLC's holdings in DexCom were worth $465,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC boosted its position in DexCom by 257.7% in the 4th quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock valued at $1,290,000 after buying an additional 11,946 shares during the last quarter. Bank Pictet & Cie Europe AG boosted its position in DexCom by 1.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock valued at $8,637,000 after buying an additional 2,010 shares during the last quarter. Mariner LLC boosted its position in DexCom by 1.5% in the 4th quarter. Mariner LLC now owns 29,729 shares of the medical device company's stock valued at $2,312,000 after buying an additional 442 shares during the last quarter. First Trust Advisors LP boosted its position in DexCom by 23.7% in the 4th quarter. First Trust Advisors LP now owns 557,899 shares of the medical device company's stock valued at $43,388,000 after buying an additional 106,754 shares during the last quarter. Finally, MML Investors Services LLC boosted its position in DexCom by 17.0% in the 4th quarter. MML Investors Services LLC now owns 36,235 shares of the medical device company's stock valued at $2,818,000 after buying an additional 5,260 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at DexCom

In related news, Director Mark G. Foletta sold 2,750 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares in the company, valued at $4,143,868.26. This represents a 5.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $88.99, for a total transaction of $130,459.34. Following the completion of the sale, the executive vice president owned 106,689 shares in the company, valued at $9,494,254.11. The trade was a 1.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 21,906 shares of company stock worth $1,832,451 in the last ninety days. Insiders own 0.32% of the company's stock.

Wall Street Analyst Weigh In

DXCM has been the subject of a number of analyst reports. Barclays upped their price objective on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research report on Wednesday, July 30th. UBS Group upped their price objective on shares of DexCom from $105.00 to $106.00 and gave the company a "buy" rating in a research report on Thursday, July 31st. Argus started coverage on shares of DexCom in a research report on Thursday. They issued a "buy" rating and a $100.00 price objective for the company. Raymond James Financial upped their target price on shares of DexCom from $99.00 to $102.00 and gave the company a "strong-buy" rating in a research note on Thursday, July 31st. Finally, Robert W. Baird cut their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Three research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $99.89.

DexCom Stock Performance

DXCM traded up $1.64 on Friday, hitting $82.26. 3,666,928 shares of the company's stock were exchanged, compared to its average volume of 4,009,486. The firm has a market cap of $32.26 billion, a PE ratio of 57.13, a P/E/G ratio of 1.72 and a beta of 1.43. DexCom, Inc. has a twelve month low of $57.52 and a twelve month high of $93.25. The stock has a fifty day moving average of $82.81 and a two-hundred day moving average of $79.77. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.03. The firm had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. DexCom's quarterly revenue was up 15.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.43 earnings per share. DexCom has set its FY 2025 guidance at EPS. On average, research analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.